Key result
Terazosin once daily reduced supine blood pressure from baseline, but the reductions did not differ from the placebo response.
Why the study?
The antihypertensive activity and effect on blood lipids of terazosin, a new alpha1-adrenergic-receptor blocker, were compared with placebo in hypertension patients.
Does terazosin 10 mg once daily reduce blood pressure compared to placebo in patients with hypertension?
RCT (n=38)
Double-blind
randomized
Does terazosin 10 mg once daily reduce blood pressure compared to placebo in patients with hypertension?
Terazosin 10 mg once daily demonstrated greater antihypertensive activity 1-3 hours after ingestion than at the end of the 24-hour dosing interval, but did not significantly reduce supine blood pressure compared to placebo.
Answers are grounded in this paper and cite their sources.
Terazosin 10 mg daily fails to outperform placebo for supine BP reduction; challenges its antihypertensive efficacy and leaves open optimal dosing or timing.
The antihypertensive activity of terazosin, an investigational alpha 1-adrenergic-receptor blocker, and its effect on blood lipids were compared with placebo in a double-blind study. After a 3-week placebo baseline period, patients were randomized to receive terazosin (n = 22) or placebo (n = 16). The dose of terazosin was titrated over 2 weeks to a maintenance dosage of 10 mg once daily for 4 weeks. Antihypertensive efficacy was assessed: (1) at the end of the 24-hour dosing interval by comparing the average blood pressure (BP) after 3 and 4 weeks of maintenance therapy to the average BP after 2 and 3 weeks of placebo therapy, and (2) for 3 hours after drug ingestion at the final visit in comparison to the predose BP at that visit. At the end of the 24-hour dosing interval, 10 mg of terazosin reduced the mean supine systolic BP from 155.6 to 152.2 mm Hg and mean supine diastolic BP from 101.9 to 99.0 mm Hg (p less than 0.05). During the 3 hours after drug ingestion, mean supine systolic and diastolic pressures decreased maximally from 151.8 to 142.7 mm Hg (p less than 0.05) and from 99.5 to 91.0 mm Hg (p less than 0.05) respectively. No supine BP reduction differed significantly from the placebo response. During terazosin therapy there was a nonsignificant increase in mean body weight of 1.4 +/- 2.9 kg and no change in blood lipids. Thus the drug demonstrated greater antihypertensive activity 1-3 hours after ingestion than at the end of the 24-hour dosing interval.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Abraham et al. (1985) conducted an RCT in Hypertension (n=38). Terazosin vs. Placebo was evaluated on Average blood pressure reduction. Terazosin once daily reduced supine blood pressure from baseline, but the reductions did not differ from the placebo response.
Synapse has enriched 10 related papers. Consider them for comparative context: